Lv7
5008 积分 2022-03-22 加入
IFN-β Pretreatment Alleviates Allogeneic Renal Tubular Epithelial Cell–Induced NK Cell Responses via the IRF7/HLA-E/NKG2A Axis
11天前
已完结
Diethylhexyl Phthalate Induces Immune Dysregulation and is an Environmental Immune Disruptor
18天前
已完结
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
23天前
已完结
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
23天前
已完结
CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study
23天前
已完结
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
23天前
已完结
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma
23天前
已完结
Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients
23天前
已关闭
Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma
23天前
已完结
Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma
23天前
已关闭
皖公网安备34019202002308
